最高の前立腺癌医師 - トップ148名の医師

ビュレント・カラゴズ教授は腫瘍生物学と免疫療法を専門とし、アナドル医療センターにて33年の経験以上の経験を持つ腫瘍内科の専門家です。

• 著名な医療機関における腫瘍内科部門の部長
• がん研究分野における40本以上の論文の著者
• トルコ腫瘍内科学会会員
• イスタンブール・オカン大学医学部教授

イルケル・ティナイ教授は、アナドル医療センターにおいてダ・ヴィンチを用いたロボット支援前立腺摘除術を専門とし、泌尿器腫瘍学の分野をリードしています。

• 低侵襲手術および新膀胱再建術の専門家
• 泌尿器腫瘍学会 理事会メンバー
• 膀胱腫瘍研究グループ 幹事
• 欧州泌尿器科学会および米国外科学会 会員
• 英語・ドイツ語対応可能

核医学専門医

タンルクル医師は、アナドル医療センターの前立腺がん専門チームの一員として、腫瘍内科および全身療法に特化した専門知識を発揮しています。

• 腫瘍内科専門医として21年の経験以上の経歴を持つ
• 前立腺がん患者ごとの多職種カンファレンスに貢献
• 国際的な臨床研究に積極的に参加
• 主要な研修病院の腫瘍内科部門長を歴任
• 准教授の学術称号を保有

Galceran教授はバル・デブロン病院でスペインの泌尿生殖器がんユニットを率い、900件以上の手術実績と全国臨床試験を有する前立腺がんの専門家です。

• 泌尿生殖器腫瘍学における39年の経験の診療経験
• 前立腺がん免疫療法および分子診断学のパイオニア
• がん治療に関する査読付き論文120本以上の著者
• スペイン泌尿生殖器腫瘍グループ（SOGUG）の共同創設者
• ASCO・ESMOの会員であり、欧州腫瘍学認定資格を保有

Dr. Banu Atalar is a board-certified radiation oncologist (Türkiye, 2004). She is a Full Professor at Acibadem MAA University (2018–present) and a clinician at Anadolu Medical Center (2026–present). She trained at Istanbul and Cerrahpaşa. In 2011, she completed a Stanford clinical research fellowship in stereotactic radiosurgery. Her practice focuses on CNS, thoracic, and GI tumors. About 75% of her care involves SRS and MR‑guided adaptive SRS.

Her honors include the ASCO IDEA award (2004), the IASLC International Mentorship Award (2018), and H.FACR (2025). She has 72 international peer‑reviewed publications. Her leadership roles include President of the Turkish Society for Radiation Oncology (2025–27) and Chair of the ESTRO National Societies Committee (2024–27). She served on the ASCO Resource‑Stratified Guidelines Committee (2013–18) and on RSS meeting and nomination committees. She organized national congresses (2023, 2025) and has been an invited speaker at major meetings.

Dr. Sertkaya graduated from Konya Meram Science High School in 2001 and entered Gazi University Medical Faculty the same year, graduating in 2008. He completed his urology specialization at Haydarpaşa Numune Training and Research Hospital in 2014, becoming a urology specialist.

Since becoming a specialist, he has focused on the sub-branch of Andrology, attending various training sessions and conferences and performing surgeries with some of the world's leading Andrology professors. In 2017, he passed the written and oral proficiency exams conducted by the European Association of Urology, earning the title of "FEBU."

In 2020, Dr. Sertkaya achieved the rank of Associate Professor of Urology. His journey in Urology and Andrology, which began in 2008, continues at the Andro Expertise Male Health and Aesthetics Center, which he founded in 2022. He sees patients in his own clinic and performs surgeries at affiliated hospitals.

この医師は化学療法と放射線療法の専門家であり、乳がん、子宮がん、前立腺がん、消化管がん、肺がん、腎臓がん、膀胱がんを含む様々な腫瘍性疾患の治療に焦点を当てています。医師は化学療法、放射線療法、生物学的がん治療などの先進的な治療法を用い、がん治療後のリハビリテーションも提供しています。

1988年からの経験を持ち、2009年からSourasky (Ichilov) Medical Centerで上級腫瘍専門医として勤務しており、Rambam Medical CenterおよびSourasky Medical Centerで重要な役職を歴任しています。医師は30以上の科学論文に貢献しており、がん治療の臨床試験にも関与しています。

Markus Heuser教授は年間約3,000件の外科的処置を行っており、Klinikum Solingenにおける泌尿器腫瘍学のリーダーです。

• ダ・ヴィンチ前立腺摘除術などの低侵襲・ロボット支援手術を専門とする
• 泌尿器科部長として40本以上の学術論文を発表
• アウグスト・キュルテン賞を含む権威ある賞を受賞
• ゲッティンゲン大学にて泌尿器科学を教授

Prof. Hüseyin Baloğlu is a pathology specialist at Anadolu Medical Center in Gebze, Kocaeli, Turkey. He focuses on molecular pathology, surgical pathology, and tumour biopsy and diagnostics.

Education and accreditations: MD, GATA Medical School (1986). Pathology specialty training, GATA (1992). Associate Professor (Doçent), GATA (2004). Visiting scholar at Albert Einstein College of Medicine (New York) and Heidelberg University.

Achievements: author of over 600 peer‑reviewed publications. Holds a patent in molecular diagnostics for thyroid cancer. Leads liquid biopsy and precision oncology services.

ラモン・ミラルベル教授は、特に前立腺がんにおける放射線腫瘍学の世界的に著名な専門家です。CERN（欧州原子核研究機構）と協力しています。

専門分野

ミラルベル教授は、フォーカスされたラジオサージャリー（ガンマナイフ、サイバーナイフ、SIRT、IMRT）、放射線療法による前立腺がんの治療を専門としています。

職歴

• 1999年から — セントロ・メディコ・テクノンの放射線腫瘍学部門長

学歴

• 1979-1984 — サンパウ大学病院（スペイン） — 医学一般の学位、放射線腫瘍学のトレーニング
• 1983 — ロイヤルマースデン病院の放射線治療部門（英国） — トレーニング
• 1985 — シティ・オブ・ホープ国立医療センターの放射線腫瘍学部門（米国） — インターンシップ
• 1987-1989 — ハーバード大学のサイクロトロン研究所（米国） — 研究員。
• 1997 — ジュネーブ大学医学部（スイス） — 医学と外科の博士号。

受賞

• スイス放射線生物学および医学物理学会の放射線腫瘍学のためのバリアン賞

科学研究

100以上の科学的な出版物を書いています。画像誘導放射線療法、高齢者における進行した前立腺がん治療、陽子療法の研究を提供しています。

組織への所属

• スイス放射線腫瘍学会。

メリムスキー教授は、ソウラスキー医療センターの軟部組織・骨腫瘍科を率い、複雑な肉腫症例を専門としています。

• 腫瘍学における41年の経験以上の診療経験
• パリのギュスターヴ・ルシー研究所にてフェローシップ研修を修了
• ESMOサルコーマファカルティおよびASCO会員
• 整形外科腫瘍学の治療成績に関する論文を多数発表

Activities • Prevention, research and early diagnosis of cancer • Palliative care in cancer • Cytotoxic chemotherapy • Hormontherapy • Targeted treatment • Immunotherapy Education • 2004 -2010 - Istanbul University, Istanbul faculty of medicine • 2011-2015 - Istanbul University, Istanbul faculty of medicine, internal medicine specialist • 2013-2014 - Cleveland Clinic Endocrinology Department, research associate • 2016-2019 Bezmiâlem Foundation University Medical Oncology Subdivision • Dissertation: Prognostic value of absolute monocyte count in patients with mantle cell lymphoma. • Subdivision Dissertation: An effect of adjuvant chemotherapy on lipid profile and anthropometric parameters in patients with breast and colon cancer. Publications • Circulating Thyroid-Stimulating Hormone Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma. Aliyev A, Gupta M, et al. Endocr  18. • The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer. • Aliyev A, Soundararajan S, Bucak E et al. Surgery.  • Diagnostic accuracy of circulating thyrotropin receptor messenger RNA combined with neck ultrasonography in patients with Bethesda III-V thyroid cytology. Aliyev A, Patel J, Brainard J, et al. Surgery.2016 Jan;159(1):113-7. doi: 10.1016/j.surg.2015.06.063. Epub 2015 Oct 9. • Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients. Seker M, Aliyev A, et al. Oncol Res Treat. Epub 2018 Aug 20. • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes. Esin E, Oksuzoglu B, Bilici A, Aliyev A. Cancer Chemother Pharmacol.2019 Jan; Epub 2018 Oct 30. • Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Turk HM, Aliyev A, Celik RS. Curr Probl Cancer.2019 Jul 29. pii: currproblcancer.2019.06.009. • Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience. Tarik Demir, Murat Araz, Altay Aliyev. Medicine Science International Medicine Journal. • Oral presentations 

Dr. Enrique Grande, MD, PhD, MSc, is a medical oncologist with more than 20 years of experience. He is an international expert in genitourinary and neuroendocrine tumors. He directs the Medical Oncology Department and the One Oncology Madrid Cancer Program at QuirónSalud, Spain’s largest private healthcare network. He leads an integrated, multidisciplinary model with access to targeted therapies and clinical trials.

He is a pioneer in precision oncology. He uses molecular profiling and biomarker-based care. He has authored more than 300 peer-reviewed papers. He serves as a principal investigator and sits on steering committees for many international trials. These studies help set standards of care in urothelial bladder and neuroendocrine tumors. He contributes to guidelines and programs at ESMO, ASCO, ENETS, and EAU.

Education/Academic Experience

Apr 1995 – Oct 2001                Medical School of Aristotle University of Thessaloniki, Greece

Mar 2007                                   IELTS Certificate (Overall Band Score 7.5)

Feb 2011                                    CCST in Urology, Aristotle University of Thessaloniki, Greece

June 2012                                  Fellow of the European Board of Urology (FEBU)

Sept 2014                                  Fellow in Andrology/Reconstructive Surgery (Mr Giulio Garaffa,         UCLH / Mid-Essex)

Apr 2016                                   Fellow of the Royal College of Surgeons of England (FRCS Eng)

Oct 2018                                   Honorary Senior Lecturer St Andrews University

Sep 2019                                   Urology ChM Tutor in Andrology and Minimally Invasive Surgery (MIMS) University of Edinburgh

Aug 2020                                  European Union Expert Panel Member of in vitro Medical Devices (EU EXPAMED)

Current and Previous appointments

Current appointment

May 2022- Present         Consultant Urologist German Oncology Centre, Limassol, Cyprus

Previous appointments

Nov16- May 2021       Consultant Urological Surgeon Victoria/ Queen Margaret Hospital Fife, Scotland.

Nov 2012 - Oct 2016      Consultant Urologist Broomfield Hospital, Mid-Essex Hospitals Trust 

Jan 2011 - Oct 2012      Urology Clinical Research Fellow, Spelialist Registrar Level), Bristol Royal Infirmary, United Bristol Hospitals Trust

Dec 2009 -Dec 2010      Urology Resident G. Gennimatas Hospital, Aristotle University of Thessaloniki

Duties

• Performing routine and major Penile / Urethral Reconstruction as well as Core Urology procedures twice weekly at Victoria and Queen Margaret Hospitals (Green light prostatectomy, Urolift Service lead, Prostate template biopsies, General urology)

Consultant Urologist providing and supervising the services of andrology and urethral reconstruction surgery. Also covering a general urology one stop outpatient clinics three times per week (Victoria and Queen Margaret Hospitals).

Participation in once weekly local cancer and once monthly specialist male uro-genital reconstruction MDT meetings (Honorary contract at the Western General Hospital, Edinburgh) as well as grand ward rounds.

Undergraduate student trainer and member of examiners panel at St Andrews University, Scotland.

Participation in 1:9 on call Urology Consultant rota.

Research

• Victoria Hospital, Kirkcaldy (NHS Fife) lead investigator. A prospective, multicentre study with subgroup randomisation into MRI-U/S image fusion guided prostate biopsies and routine transrectal U/S guided biopsies.  (MULTIPROS Study)
•  
• Broomfield Hospital (MEHT) sub-investigator. A pragmatic multicentre randomised superiority trial of open urethroplasty versus endoscopic urethrotomy. (OPEN Study)
•  
• Broomfield Hospital (MEHT) sub-investigator. A Multicentre randomised controlled trial of extracorporeal shockwave lithotripsy, as first treatment option, compared with direct progression to ureteroscopic treatment, for ureteric stones. (TISU
• Study)
•  
• Bristol Royal Infirmary sub-investigator. A Multicentre Randomised Controlled Trial of the Use of Drug Therapy in the Management of Symptomatic Ureteric Stones in Hospitalised Patients. (SUSPEND Study)
•  
• Bristol Royal Infirmary sub-investigator. A Multicentre Prospective Single Arm Intervention Trial Evaluating Focal Therapy using High Intensity Focused Ultrasound (Sonablate 500) for Localised Prostate Cancer. (HIFU INDEX Study)
•  
• Bristol Royal Infirmary sub-investigator, A Randomised Controlled Trial to Determine the Effect of Decapeptyl on Reduction of Prostate Volume Pre-Radiotherapy Compared with Standard Therapy (Zoladex). (EDVART Study)

Teaching Experience

Fife Simulation BPH Course Fascilitator (Scottish Urology Training Programme, Queen Margaret Hospital, Dumfermline Fife)

Urology Simulation boot camp Faculty member (St James's University Hospital, Leeds)

General Practitioner Urology Training Programme Fascilitator (ScotGem)

Objective Structured Clinical Examination (OSCE) assessor (St Andrews University Medical School)

Teaching (case-based discussions) and trainee supervision in theatres (East Anglia / East of   Scotland Deaneries trainees)

FY1 Doctors Urology teaching Bristol Royal Infirmary (University Bristol Hospitals Trust)

Undergraduate teaching of medical students in General Hospital of the city of Drama, Greece

Anatomy, Physiology and First Aid to Undergraduate nursing students

Personal Information 

Sex:  Male

Born : 1968 

Professional Experience

Gayrettepe Florence Nigthingale Hospital

Medical Oncology Department

Besiktas/Istanbul/Turkey (ongoing)

Education:

He became Professor (22/April /2016)

Medical Oncology

Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

Istanbul University Oncology Institue,

Department of Medical Oncology

Medical Oncology Fellowship (December 2001-December2004)

Istanbul University, Istanbul Medical Faculty

Hemodialysis Traning (May1996-January1997)

Istanbul University ,bCerrahpasa Medical Faculty

Internal Medicine Residency (November 1991-November 1996)

Istanbul University ,bCerrahpasa Medical Faculty

Ege University Medical Faculty (1985-1991)

Professional Experience

February 1999-November 2001

Metropolitan Florence Nigthingale Hospital

American Cancer Center, Gayrettepe/İstanbul

April1997- October 1998

Bayraktar Dialysis Center

Güngören/ Istanbul

Membership

Turkish Medical Oncology Association

ENET(European Neuroendocrine Tumour Society)

ESMO

ASCO

Education and Specialization

• Faculty of Medicine, Hacettepe University
• 1999 - Akdeniz University, Faculty of Internal Medicine, Internal Medicine Specialization Training
• Internal Medicine Specialization Training in the USA, Akdeniz University (2013 - 2014)
• Internal Medicine Specialization Training in the USA (2013 - 2014) - Medical Oncology Department
• Akdeniz University, Faculty of Medicine, Department of Medical Oncology (Received Associate Professorship title)

Work Experience

• 2009 - Kayseri Training and Research Hospital, Hospital
• Acıbadem Kayseri
• 2017 - 2018 - Lara Private Anadolu Hospital
• 2018 - Medical Park Antalya Hospital Complex

Expertise

• Diagnosis of organ tumors
• Chemotherapy in cancer treatment
• Targeted cancer therapies
• Immunotherapy in cancer treatment
• Next-generation genetic research in cancer treatment
• Complementary medicine in cancer treatment
• Medical oncology

Dr. David Kuczer is a specialist in radio-oncology with many years of experience in cancer diagnosis and treatment. He offers fast access to precise radiotherapy based on current scientific standards.

He is a member of the Cancer Center at the Vienna Private Clinic. He presents each patient to the in-house tumor board. This allows an interdisciplinary discussion by an internationally renowned team and helps select the best treatment.

All radiation treatments are provided in close cooperation with Amethyst Radiotherapy at the Vienna Private Clinic.

Personal information

Title: Professor Doctor

Branch: Radiation Oncology

Work History:

1 GATA Military Medical Faculty

2 Gayrettepe Florence Nightingale Hospital

3 T.R. Demiroğlu Bilim University \ Associate Professor

4 T.R Demiroğlu Bilim University \ Professor

Medical Specialties and Subspecialties:

1 Head and Neck Cancers

2 Radiation Oncology

Priority treatments:

1 Prostate cancer

2 Conformal treatments

Special advanced health technologies:

1 Truebeam Stx Technology

2 Halcyons

Education

1991 - Istanbul University Istanbul Faculty of Medicine

1996 - Istanbul University Cerrahpaşa Faculty of Medicine Radiation

Oncology Specialization Training

アントニオ・アルカラス博士はテクノン医療センター（バルセロナ、スペイン）の泌尿器科および腎移植部門を率いています。

アントニオ・アルカラス博士は、30年以上の経験を持つスペインの有名な外科医、泌尿器腫瘍学者、移植専門医です。彼のマネジメントの下、泌尿生殖器系の病理を治療するために500を超える成功した手術が行われました。多くの外科的介入は、低侵襲技術（腹腔鏡による経膣的腎臓摘出術、腎摘出術、腎移植を含む）で行われました。アントニオ・アルカラスの主な専門分野は、前立腺癌の治療です。

腎臓、膀胱、副腎、精巣、尿管、および他の泌尿器系の臓器の腫瘍性疾患の治療は、ダ・ヴィンチ手術ロボットシステムを用いた伝統的な外科的方法および革新的な方法によって提供されます。

アントニオ・アルカラス博士はまた、たとえば停留精巣のような子供の先天性病態も治療します。

医師は下記のような権威ある専門コミュニティのメンバーです：

• アメリカ泌尿科連合；
• スペイン泌尿器科協会；
• 欧州泌尿器科学会。